

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT

**UNAUDITED OPERATING RESULTS
FOR THE THREE MONTHS ENDED 31 MARCH 2026**

This announcement is made by SSY Group Limited (the “Company”) on a voluntary basis.

The board of directors (the “Board”) of the Company is pleased to announce the following unaudited operating results of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2026 based on its management accounts which have not been audited or reviewed by the auditor of the Company.

The unaudited turnover of the Group for the three months ended 31 March 2026 was approximately HK\$1,227 million (same period of 2025: approximately HK\$1,136 million), representing an increase of 8.0% as compared with corresponding period of last year. The unaudited gross profit of the Group for the three months ended 31 March 2026 was approximately HK\$502 million (same period of 2025: approximately HK\$509 million), representing a decrease of 1.3% as compared with corresponding period of last year, with an unaudited gross profit margin of approximately 41.0%, representing a decrease of 3.8 percentage point as compared with corresponding period of last year. For the three months ended 31 March 2026, the Group’s unaudited profit attributable to the shareholders of the Company (the “Shareholders”) was approximately HK\$ 171,206,000, representing an increase of 1.6% as compared with corresponding period of last year (same period of 2025: approximately HK\$ 168,470,000).

For the three months ended 31 March 2026, the abovementioned unaudited turnover of the Group of approximately HK\$1,227 million was comprised of the following:

For the three months ended 31 March 2026	Unaudited turnover (HK\$)	Increase /(decrease) from same period of 2025	% of unaudited turnover
Intravenous infusion (“IV”) solution products (including subcontracting products)			
Non-PVC soft bag IV solution	325 million	2.7%	26.5%
Upright soft bag IV solution	186 million	20.7%	15.2%
PP plastic bottle IV solution	138 million	(2.4)%	11.2%
Glass bottle IV solution	47 million	18.8%	3.9%
Non-IV solution products			
Ampoule injection	78 million	0.2%	6.3%
Bulk pharmaceuticals	316 million	61.2%	25.8%
Oral preparations	73 million	(51.8)%	6.0%
Medical materials	56 million	10.1%	4.5%
Other products and services	8 million	(7.5)%	0.6%

Shareholders and potential investors should note that above financial information for the three months ended 31 March 2026 contained in this announcement is based on the Group’s unaudited management accounts. Accordingly, such information shall in no way be regarded as to provide any indication of the audited financial results of the Group for the three months ended 31 March 2026 or any assurance on such audited financial results. Such information may differ from the information to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of compiling such operating results information.

Shareholders and potential investors are advised to exercise caution in dealing in the securities of the Company.

On behalf of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 4 May 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.